REGN Regeneron Pharmaceuticals, Inc.
$713.59
▼ 1.03%
50
Value
56
P/E16.78
65
P/B2.36
47
P/S4.93
47
EV/EBITDA12.75
62
Growth
39
Revenue Growth1.0%
30
EPS Growth5.3%
43
FCF Growth11.3%
45
Momentum
57
12-Month Return27.4%
67
3-Month Return-7.2%
49
1-Month Return-8.2%
38
RSI (14)38.74
50
50/200 MABullish
75
Profitability
59
ROE14.3%
54
ROA10.8%
61
Gross Margin84.5%
68
Operating Margin24.3%
55
Net Margin29.6%
72
FCF Yield5.7%
50
Risk
41
Beta0.30
35
60-Day Volatility29.5%
47
The QScore of 50 indicates a neutral outlook for Regeneron Pharmaceuticals, with the long-term and short-term scores closely aligned. The stock scores high on value, momentum, and profitability, driven by its reasonable P/E of 16.8 and strong margins, including an operating margin of 24.3% and gross margin of 84.5%. However, its growth score is lower due to modest revenue growth of 1.0% and the risk score is also a drag, reflecting low beta but high volatility.